Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT07235683RecruitingPhase 4
Stronger CMV treatment for lung transplant recipients
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Toronto, OntarioAges 18 years+ - NCT05579678Recruiting
Personal rehab program after donor bone marrow transplant
This study looks at a personalized rehabilitation program for people who are eligible to receive a bone marrow transplant from a donor. The goal is to improve recovery and function after transplant.
Edmonton, AlbertaAges 18–70 - NCT07234591Recruiting
Study of an oral medication for moderate to severe plaque psoriasis
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
ShanghaiAges 18–70 - NCT07342803RecruitingPhase 2
LP-003 injection for allergic asthma
This trial tests an injection called LP-003 for people with allergic asthma that is not well controlled by current inhalers and other medications. It aims to see if the drug can improve asthma control and reduce flare-ups.
ShanghaiAges 18–75 - NCT06528197Recruiting
Building a better treatment model for Sjögren's syndrome
This study is building a new model to help doctors treat primary Sjögren's syndrome using a combination of traditional Chinese medicine and Western medicine. It may help find better ways to manage your symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT05514015RecruitingPhase 4
Rituximab with steroids or rituximab alone for membranous kidney disease
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
Guangzhou, GuangdongAges 18–75 - NCT05734794RecruitingPhase 3
Rituximab for new childhood nephrotic syndrome
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
Hangzhou, ZhejiangAges 2–17 - NCT05663216Recruiting
Study of fluid leaks in serious whole-body inflammation
This trial looks at what causes blood vessels to “leak” fluid during a dangerous whole-body inflammation response. It may help doctors understand why some people develop fluid buildup and aim for better monitoring and care in the ICU.
ParisAges 18 years+ - NCT04877288RecruitingPhase 3
Switch some teen kidney transplant patients to belatacept
This Phase 3 study tests whether switching teens from one anti-rejection medicine to belatacept works as well as staying on the current regimen. It also looks at safety and whether patients can stay on their anti-rejection medicines.
Birmingham, AlabamaAges 12–17 - NCT04871035Recruiting
Compare immunoadsorption vs plasma exchange for Guillain-Barré
This study tests whether immunoadsorption works as well as plasma exchange to improve symptoms in people with Guillain-Barré syndrome. The goal is to find which treatment helps recovery and is safer for patients.
Ulm, Baden-WurttembergAges 18 years+ - NCT07266116RecruitingPhase 1/Phase 2
TQB2934 injection for light chain amyloidosis
This trial tests a new injectable drug called TQB2934 for people with systemic light chain amyloidosis. It aims to see if the drug is safe and effective for those whose disease has come back or gotten worse after previous treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT07206823Recruiting
Romiplostim N01 plus rituximab for ITP that didn't respond to oral TPO-RA
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
Suzhou, JiangsuAges 14 years+ - NCT04837859RecruitingPhase 2
Personalized immunotherapy for early-stage unfavorable Hodgkin lymphoma
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
CologneAges 18 years+ - NCT04804891RecruitingPhase 1
Personalized immune medicine plan after intestinal transplant
This Phase 1 study tests a way to lower (minimize) the immune-suppressing medicines after an intestinal transplant while still keeping the new organ safe. It uses blood tests that look at immune activity and “chimerism” to guide how strong the immune suppression needs to be.
New York, New YorkAges 18–65 - NCT07197099Recruiting
Plasma exchange for immune-related nerve diseases
This study looks at whether removing and replacing blood plasma (called therapeutic plasma exchange or TPE) can help people with immune-related nerve or brain conditions. It includes both new and returning cases that meet standard guidelines for this treatment.
CairoAges Any age - NCT07258771RecruitingPhase 4
Upadacitinib plus steroids vs steroids alone for severe ulcerative colitis
This trial tests if adding upadacitinib (a pill) to standard steroid treatment helps people with a severe flare of ulcerative colitis feel better faster. You may qualify if you are having frequent bloody stools and signs of serious inflammation, and you haven't tried upadacitinib before.
Ann Arbor, MichiganAges 18–75 - NCT06047977RecruitingPhase 1
Immune cell therapy for high-risk solid tumors in children and young adults
This trial uses a patient's own tumor-fighting immune cells (TILs) to treat high-risk solid tumors outside the brain in children and young adults. It has two parts: first, a tumor sample is collected during surgery, and then the immune cells are grown in a lab and given back to the patient to attack the cancer.
St. Petersburg, FloridaAges 1–21 - NCT07189390RecruitingPhase 2
Probiotic study for infants who had antibiotics at birth
This study tests whether giving a probiotic (a 'good' bacteria) to babies who received antibiotics shortly after birth can help their developing gut and immune system. Participants will receive a daily probiotic or placebo for about 6 weeks, and their health will be monitored.
Adelaide, South AustraliaAges Up to 4 weeks - NCT07184814Recruiting
Takayasu's arteritis with lung artery involvement study
This study looks at people with Takayasu's arteritis that also affects the lungs' blood vessels. Researchers want to understand the disease's behavior and outcomes over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06849193Recruiting
Predicting treatment outcomes in advanced bile duct cancer
This study looks at how well current chemotherapy and immunotherapy work for advanced bile duct or gallbladder cancers that cannot be removed by surgery. Researchers will collect data from multiple centers to build a model that helps predict how patients may respond to treatment.
Nanjing, JiangsuAges 18 years+ - NCT06819774RecruitingPhase 3
Testing cetirizine injection for acute hives
This trial tests an injectable medication (cetirizine, a type of antihistamine) to see if it quickly relieves itching and hives in adults with acute (short-term) hives. It is for people whose hives have lasted less than 6 weeks and who still have bothersome symptoms.
Beijing, Beijing MunicipalityAges 18–65 - NCT07158814RecruitingPhase 4
Testing the safety of an RSV antibody in infants
This study checks if it is safe to delay the RSV preventive antibody shot by up to two weeks in infants who are getting their routine vaccines. Your baby will get the antibody at a second visit.
Oakland, CaliforniaAges 1 month–7 months - NCT06819280Recruiting
Immune cells for advanced colorectal cancer after first treatment
This trial tests whether your own immune cells, called tumor-infiltrating lymphocytes (TILs), can be grown in a lab and given back to you to fight advanced colorectal cancer. It is for people whose cancer has continued to grow after their first round of chemotherapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06569680RecruitingPhase 2
Mosunetuzumab for untreated extranodal marginal zone lymphoma
This trial tests a new drug called mosunetuzumab for people with a type of slow-growing lymphoma (extranodal marginal zone lymphoma) that has not been treated before. The goal is to see if the drug helps shrink the lymphoma and control the disease.
Miami, FloridaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.